Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395752 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C19PRKD1TP53 | |
| SCHEMBL30392254 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C19PRKD1TP53 | |
| SCHEMBL3143409 | 0.84 | CYP1A2 (0.74) | CYP1A2CYP3A4CYP2C19PRKD1ALDH1A1 | |
| SCHEMBL10791718 | 0.81 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2C19PRKD1TP53 | |
| SCHEMBL30663248 | 0.79 | CYP3A4 (0.68) | CYP1A2CYP3A4CYP2C19PRKD1TP53 | |
| SCHEMBL10793789 | 0.79 | ALDH1A1 (0.77) | CYP1A2CYP3A4CYP2C19PRKD1TP53 | |
| SCHEMBL3866703 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19TP53ALDH1A1 | |
| SCHEMBL15781372 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19TP53HSD17B10 | |
| SCHEMBL3864592 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19TP53ALDH1A1 | |
| SCHEMBL10401284 | 0.78 | CYP3A4 (0.66) | CYP1A2CYP3A4CYP2C19PRKD1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995027715-A2 | METHOD OF MANUFACTURE OF (-)GALANTHAMINE IN HIGH YIELD AND PURITY SUBSTANTIALLY FREE OF EPIGALANTHAMINE | CIBA-GEIGY CORPORATION (US) | 1995-10-19 | — | — | WO | claimed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| CN-112225713-B | Synthesis process of 5-hydroxybenzofuran compound | 华东理工大学 | 2023-02-28 | — | — | CN | disclosed |
| CN-112225713-A | Synthesis process of 5-hydroxybenzofuran compound | 华东理工大学 | 2021-01-15 | — | — | CN | disclosed |
| WO-2013033245-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-5604280-A | PHOTOCHROMIC | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 1997-02-18 | — | — | US | disclosed |
| WO-1995027716-A1 | 6,7-HETEROANNEALED 2,2-DIPHENYL CHROMENES AND USE THEREOF IN OPHTHALMIC OPTICS | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 1995-10-19 | — | — | WO | disclosed |
| WO-1995027715-A2 | METHOD OF MANUFACTURE OF (-)GALANTHAMINE IN HIGH YIELD AND PURITY SUBSTANTIALLY FREE OF EPIGALANTHAMINE | CIBA-GEIGY CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0676401-A1 | Annelated spirofluorene-2H-benzopyrans and their use in ophthalmic optics | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIA4, GRIA3, GRIN3A | CYP1A2 400/4885CYP3A4 238/4885CYP2C19 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.